Stockreport

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025 [Yahoo! Finance]

Jade Biosciences, Inc.  (JBIO) 
PDF JADE101 is an investigational, potentially best-in-class disease-modifying anti-APRIL monoclonal antibody, with a Phase 1 healthy volunteer study underway SAN FRANCIS [Read more]